CA3031069A1 - Methods of treating dry eye syndrome - Google Patents

Methods of treating dry eye syndrome Download PDF

Info

Publication number
CA3031069A1
CA3031069A1 CA3031069A CA3031069A CA3031069A1 CA 3031069 A1 CA3031069 A1 CA 3031069A1 CA 3031069 A CA3031069 A CA 3031069A CA 3031069 A CA3031069 A CA 3031069A CA 3031069 A1 CA3031069 A1 CA 3031069A1
Authority
CA
Canada
Prior art keywords
beta
subject
composition
eye
des
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3031069A
Other languages
English (en)
French (fr)
Inventor
Won Suk Yang
Sin Wook Kang
Kyoungsun Kim
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
RegenTree LLC
Original Assignee
RegenTree LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by RegenTree LLC filed Critical RegenTree LLC
Publication of CA3031069A1 publication Critical patent/CA3031069A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2292—Thymosin; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
CA3031069A 2016-07-18 2017-07-17 Methods of treating dry eye syndrome Pending CA3031069A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201662363565P 2016-07-18 2016-07-18
US201662363592P 2016-07-18 2016-07-18
US62/363,565 2016-07-18
US62/363,592 2016-07-18
US201662436727P 2016-12-20 2016-12-20
US62/436,727 2016-12-20
PCT/US2017/042382 WO2018017479A1 (en) 2016-07-18 2017-07-17 Methods of treating dry eye syndrome

Publications (1)

Publication Number Publication Date
CA3031069A1 true CA3031069A1 (en) 2018-01-25

Family

ID=60992530

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3031069A Pending CA3031069A1 (en) 2016-07-18 2017-07-17 Methods of treating dry eye syndrome

Country Status (8)

Country Link
US (2) US10960051B2 (https=)
EP (1) EP3484497A4 (https=)
JP (1) JP6889771B2 (https=)
KR (1) KR102488796B1 (https=)
CN (1) CN109789182A (https=)
AU (1) AU2017300268B2 (https=)
CA (1) CA3031069A1 (https=)
WO (1) WO2018017479A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7570228B2 (ja) * 2020-12-25 2024-10-21 ライオン株式会社 機械学習実行プログラム、ドライアイ検査プログラム、機械学習実行装置及びドライアイ検査装置
JP2022102757A (ja) * 2020-12-25 2022-07-07 ライオン株式会社 機械学習実行プログラム、ドライアイ検査プログラム、機械学習実行装置及びドライアイ検査装置
JP7570229B2 (ja) * 2020-12-25 2024-10-21 ライオン株式会社 機械学習実行プログラム、ドライアイ検査プログラム、機械学習実行装置及びドライアイ検査装置

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05503527A (ja) 1990-02-22 1993-06-10 マクノート・ピーティーワイ・リミテッド 人工涙液
US20080096817A1 (en) * 1998-07-30 2008-04-24 Regenerx Biopharmaceuticals, Inc. METHODS OF TREATING DISORDERS OF THE EYE AND SURROUNDING TISSUE WITH THYMOSIN BETA 4 (Tbeta4), ANALOGUES, ISOFORMS AND OTHER DERIVATIVES
AU2002255736B2 (en) 2001-03-15 2006-08-31 Regenerx, Biopharmaceuticals, Inc. Methods of treating disorders of the eye and surrounding tissue with thymosin beta4 (Tbeta4), analogues, isoforms and other derivatives
WO2003020215A2 (en) * 2001-08-29 2003-03-13 Regenerx Biopharmaceuticals, Inc. Methods of treating mycocardial event related coditions with thymosin beta 4
ES2619426T3 (es) * 2005-01-13 2017-06-26 Regenerx Biopharmaceuticals, Inc. Timosina beta 4 para el tratamiento de la esclerosis múltiple
CN101198344A (zh) * 2005-06-17 2008-06-11 雷金纳克斯生物制药公司 冻干的或可冻干形式的lkktet和/或lkktnt肽组合物
JP2008543877A (ja) * 2005-06-17 2008-12-04 リジェナークス・バイオファーマスーティカルズ・インコーポレイテッド Ｌｋｋｔｅｔおよび／またはｌｋｋｔｎｔ組成物および組織の悪化、傷害または損傷を処置または予防するための方法
CN101152568A (zh) * 2006-09-25 2008-04-02 宝勒日 具有促进血管形成、组织再生及伤口愈合作用的多肽组合制剂
NZ582188A (en) * 2007-07-11 2012-03-30 Pfizer Pharmaceutical compositions and methods of treating dry eye disorders

Also Published As

Publication number Publication date
JP6889771B2 (ja) 2021-06-18
US20190240294A1 (en) 2019-08-08
JP2019525923A (ja) 2019-09-12
WO2018017479A1 (en) 2018-01-25
AU2017300268B2 (en) 2024-06-13
EP3484497A1 (en) 2019-05-22
CN109789182A (zh) 2019-05-21
EP3484497A4 (en) 2020-01-01
US20210213103A1 (en) 2021-07-15
AU2017300268A1 (en) 2019-01-31
KR102488796B1 (ko) 2023-01-13
US10960051B2 (en) 2021-03-30
KR20190031280A (ko) 2019-03-25

Similar Documents

Publication Publication Date Title
US9585941B2 (en) Eye drop formulation
RU2700927C2 (ru) Офтальмологическая композиция, содержащая циклоспорин и трегалозу
US20210213103A1 (en) Methods of treating dry eye syndrome
AU2006260184B2 (en) Prophylactic or therapeutic agent for corneal/conjunctival disease
WO2010107069A1 (ja) アミノ酸含有眼科用組成物
EP3338792B1 (en) Corneal damage prevention/treatment composition comprising thymosin beta 4 and citric acid as active ingredients
Tu et al. Dry eye
HK40012612A (en) Methods of treating dry eye syndrome
US20260021159A1 (en) Stable peptide compositions and methods of use thereof for treatment of moderate/severe dry eye-related ocular symptoms
WO2020128616A2 (en) Methods and compositions for controlling cell migration and proliferation
HK1256177A1 (en) Lkktet and/or lkktnt peptide compositions which are lyophilized or in a form capable of being lyophilized

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220503

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 7TH ANNIV.) - STANDARD

Year of fee payment: 7

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D00-D120 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: VOLUNTARY SUBMISSION OF PRIOR ART RECEIVED

Effective date: 20240708

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20240805

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20241120

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250129

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D00-D123 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRIOR ART DISCLOSURE DETERMINED COMPLIANT

Effective date: 20250317

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250317

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250527

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250527

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 8TH ANNIV.) - STANDARD

Year of fee payment: 8

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250718

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250718

D22 Grant of ip right intended

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D22-D128 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALLOWANCE REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20251224

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260107

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260108